NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients

Iimura, Yohei; Shimomura, Hitoshi; Yasu, Takeo; Imanaka, Keiko; Ogawa, Ryuichi; Ito, Akihiko; Suzuki, Kenichi; Yamaguchi, Gaku; Kawasaki, Norihisa; Konaka, Chimori

doi:10.5414/cp203323

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previous study findings on low-molecularweight EGFR inhibitors, 8,9) the present findings suggest that oral NSAIDs may suppress acne-like eruptions caused by anti-EGFR antibodies. Based on this evidence, acne-like eruption caused by the anti-EGFR antibody may be affected by the expression of COX-2.…”

Section: Discussionsupporting

confidence: 93%

“…Meanwhile, acne-like eruptions caused by low-molecularweight EGFR inhibitors may be alleviated by oral administra-tion of non-steroidal anti-inflammatory drugs (NSAIDs). 8,9) EGFR inhibition increases the expression of cyclooxygenase (COX)-2 via the peroxisome proliferator-activated receptor γ (PPARγ) and induces the production of inflammatory cytokine tumor necrosis factor α (TNFα), which may trigger acne-like eruptions. 10) NSAIDs may suppress the action of COX-2 expressed by this mechanism and may thus prevent the development of acne-like eruptions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevention of Acne-Like Eruption Caused by Panitumumab Treatment through Oral Administration of Non-steroidal Anti-inflammatory Drugs

Tanaka

Ishikawa

Sato

et al. 2022

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Acne-like eruption caused by anti-epidermal growth factor receptor (EGFR) antibodies such as panitumumab reduces treatment adherence and patient QOL; an alternative therapy is desired. Meanwhile, the usefulness of oral Non-steroidal Anti-inflammatory Drugs (NSAIDs) for acne-like eruptions caused by lowmolecular-weight EGFR inhibitors such as erlotinib has been reported in the treatment of lung cancer. This study aimed to investigate whether the combined use of oral NSAIDs and panitumumab for colorectal cancer patients helps prevent acne-like eruption. We retrospectively investigated 167 colorectal cancer patients who had been treated with panitumumab for three cycles or more. The observation period was set from the start of panitumumab treatment to the end of three cycles. Within this period, the incidence and severity of acne-like eruptions were compared. A total of 59 and 108 patients were in the NSAIDs use and non-use groups, respectively, showing differences in the incidence of acne-like eruption rates (78.0 vs. 90.7%, respectively; p 0.033). In the use group, eruption severity grades 0, 1, 2, and 3 were observed in 13, 33, 13, and 0 patients, respectively; the corresponding values in the non-use group were 10, 60, 36, and 2, respectively (p 0.007). Oral NSAIDs may help prevent acne-like eruptions caused by panitumumab.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Prevention of Acne-Like Eruption Caused by Panitumumab Treatment through Oral Administration of Non-steroidal Anti-inflammatory Drugs

Tanaka

Ishikawa

Sato

et al. 2022

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…In addition to the aforementioned studies on the preventive use of antibiotics, nonsteroidal anti-inflammatory drugs may also play a role in preventing EGFR inhibitor-related rashes ( 186 ). Local prophylactic use of 3% chloramphenicol + 0.5% prednisolone ointment significantly reduced the severity of facial papulopustular exanthemas induced by EGFR inhibitors ( 175 ).…”

Section: Therapeutic Strategies For Skin Toxicitymentioning

confidence: 99%

Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies

Duan

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of cancers such as non-small cell lung cancer, head and neck cancer, breast cancer, pancreatic cancer. Adverse reactions such as skin toxicity, interstitial lung disease, hepatotoxicity, ocular toxicity, hypomagnesemia, stomatitis, and diarrhea may occur during treatment. Because the EGFR signaling pathway is important for maintaining normal physiological skin function. Adverse skin reactions occurred in up to 90% of cancer patients treated with EGFR inhibitors, including common skin toxicities (such as papulopustular exanthemas, paronychia, hair changes) and rare fatal skin toxicities (e.g., Stevens–Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis). This has led to the dose reduction or discontinuation of EGFR inhibitors in the treatment of cancer. Recently, progress has been made about research on the skin toxicity of EGFR inhibitors. Here, we summarize the mechanism of skin toxicity caused by EGFR inhibitors, measures to prevent severe fatal skin toxicity, and provide reference for medical staff how to give care and treatment after adverse skin reactions.

show abstract

“…Recent research has identified that NSAIDs have suppressing effects on cigarette smoke-induced lung tumors, either mainstream (MCS) or environmental (ECS) in mice [ 51 ]. Izzotti and colleagues analyzed 1135 miRNAs in the lung and serum of mice subjected to smoke and/or oral usage of either aspirin (1600 mg/kg) or naproxen (320 mg/kg).…”

Section: Effects Of Aspirin On Ncrnas In Different Conditionsmentioning

confidence: 99%

Noncoding RNA Roles in Pharmacogenomic Responses to Aspirin: New Molecular Mechanisms for an Old Drug

Tabari

Mishan

Moradi

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Aspirin, as one of the most frequently prescribed drugs, can have therapeutic effects on different conditions such as cardiovascular and metabolic disorders and malignancies. The effects of this common cardiovascular drug are exerted through different molecular and cellular pathways. Altered noncoding RNA (ncRNA) expression profiles during aspirin treatments indicate a close relationship between these regulatory molecules and aspirin effects through regulating gene expressions. A better understanding of the molecular networks contributing to aspirin efficacy would help optimize efficient therapies for this very popular drug. This review is aimed at discussing and highlighting the identified interactions between aspirin and ncRNAs and their targeting pathways and better understanding pharmacogenetic responses to aspirin.

show abstract

NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients

Cited by 6 publications

References 0 publications

Prevention of Acne-Like Eruption Caused by Panitumumab Treatment through Oral Administration of Non-steroidal Anti-inflammatory Drugs

Prevention of Acne-Like Eruption Caused by Panitumumab Treatment through Oral Administration of Non-steroidal Anti-inflammatory Drugs

Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies

Noncoding RNA Roles in Pharmacogenomic Responses to Aspirin: New Molecular Mechanisms for an Old Drug

Contact Info

Product

Resources

About